The Effect of Anti-inflammatory Analgesics on Pain Following Hallux Valgus Surgery
Primary Purpose
Postoperative Pain
Status
Completed
Phase
Phase 4
Locations
Sweden
Study Type
Interventional
Intervention
etoricoxib
tramadol
Sponsored by
About this trial
This is an interventional treatment trial for Postoperative Pain focused on measuring Day surgery, Hallux Valgus, Pain, Analgesics
Eligibility Criteria
Inclusion Criteria:
- Health ASA 1-2 patients 18-65 years of age
Exclusion Criteria:
- ASA/NSAID allergy
- Renal disease
- Lithium therapy
- Complicated cardiovascular disease
Sites / Locations
- Foot & Ancle Surgical Center
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Active Comparator
Arm Label
1
2
Arm Description
Active study drug: Etoricoxib 90 mg once daily
Tramadol 100 mg slow release twice daily
Outcomes
Primary Outcome Measures
Number of Patients Requiring Rescue Medication
Number of patients requiring any further pain medication
Secondary Outcome Measures
Summary of Pain Scores, Day 1-7 of Visual Analogue Scale Grading of Pain
VAS score 1-10 1=no pain 10 = worst possible pain, summary variable day 1-7; 7 - 70
Compliance to Base Medication
Number of patients that did not discontinue study medication before day 7
Gastro-intestinal Symptoms
Number of patients reporting any gastro-intestinal side effects; nausea and or vomiting, gastritis etc. assessed by patient and documented in written questionnaire
Dizziness/Sleepiness
Number of patients that experienced dizziness/sleepiness/fatigue, assessed by patient and documented in written questionnaire
Wound Healing
healing process assessed by a blinded physician during the final outpatient clinic visit assessment graded; Good/neutral/bad
Satisfaction With Pain Medication
satisfied or unsatisfied with study medication, assessed by patient in questionnaire
Patient Assessed Overall Satisfaction With Surgery/Outcome
overall satisfaction with outcome, patients assessed satisfaction with the surgical procedure; satisfied, neutral or unsatisfied, written questionnaire.
Patient Assessed Quality of Life
Quality of Life evaluated by grading on a Visual Analogue Scale in the written questionnaireisual analogue scale grading 0-100; 0 death and 100 perfect quality of life
Full Information
NCT ID
NCT00733421
First Posted
August 12, 2008
Last Updated
January 15, 2010
Sponsor
Karolinska Institutet
1. Study Identification
Unique Protocol Identification Number
NCT00733421
Brief Title
The Effect of Anti-inflammatory Analgesics on Pain Following Hallux Valgus Surgery
Official Title
The Effect of Anti-inflammatory Analgesics on Bone Repair, Pain and Gastro-intestinal Side Effects After Hallux Valgus Surgery; a Prospective Randomised Double-blind Placebo Controlled Study.
Study Type
Interventional
2. Study Status
Record Verification Date
August 2009
Overall Recruitment Status
Completed
Study Start Date
October 2008 (undefined)
Primary Completion Date
June 2009 (Actual)
Study Completion Date
August 2009 (Actual)
3. Sponsor/Collaborators
Name of the Sponsor
Karolinska Institutet
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
The effects of none-steroidal anti-inflammatory drugs (NSAIDs) and selective cyclooxygenase inhibitors (Coxibs) on the formation of bone and fracture healing have been a matter of debate since long.
There is, however, limited data in humans and further prospective randomised studies are warranted. Ekman et al studied in a prospective randomised double blind study the effects of celecoxib, a selective cox-II-inhibitor, on pain and bone healing following spine surgery. They found significant effects on reduction of pain and need for opioid analgesics postoperatively but could see no negative effects the numbers of "none-unions" at a 1-year follow up 3.
In a similar prospective randomised double-blind study design significant effects in reduction of pain and need for rescue analgesia was seen from the use of celecoxib in the perioperative multi-modal pain strategy for cruciate-ligament reconstruction and no negative effects could bee seen on six month follow-up of the strength of the reconstructed ligament.
The aim of the present study is to further study the effects of the perioperative use of etoricoxib, a selective cox-II-inhibitor (Coxibs), in a prospective randomised double-blind study on bone healing, pain and need for rescue analgesia in patients undergoing elective Hallux Valgus surgery with a standardised surgical technique including an osteotomy of metatarsale I and excision of exostosis.
Study population 100 American Society of Anesthesiology (ASA) physiological status1-2 patients scheduled for elective hallux valgus (HV) surgery
The patients are going to be randomised into 2 groups, 50 patients in each;
etoricoxib 90 mg once daily x 5
tramadol 100 mg twice daily x 5
First line rescue medication t. paracetamol 1 gr up to 4 gram daily Second line rescue t. oxycodone 10 mg
Primary study variables:
X-ray evaluation (computer tomography (CT)-investigation) of bone healing assessed a CT-scan modelling of the osteotomy at twelve weeks after surgery
Number of patients requiring rescue medication
Patient assessment using "brief pain inventory" 24 hours and 2 weeks after surgery
Secondary study variables are;
Visual Analogue Scale (VAS) grading Day 1-7
Compliance to base medication
Need for rescue analgesia Day 1-7
Adverse Effects
Experience of any emetic symptoms
Experience of any gastrointestinal symptoms
Satisfaction with pain medication Day 20
Wound dressing Day 20
Clinical evaluation 17 weeks, final assessment
Detailed Description
See brief summary
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Postoperative Pain
Keywords
Day surgery, Hallux Valgus, Pain, Analgesics
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare Provider
Allocation
Randomized
Enrollment
100 (Actual)
8. Arms, Groups, and Interventions
Arm Title
1
Arm Type
Experimental
Arm Description
Active study drug:
Etoricoxib 90 mg once daily
Arm Title
2
Arm Type
Active Comparator
Arm Description
Tramadol 100 mg slow release twice daily
Intervention Type
Drug
Intervention Name(s)
etoricoxib
Other Intervention Name(s)
Arcoxia
Intervention Description
90 mg once daily
Intervention Type
Drug
Intervention Name(s)
tramadol
Other Intervention Name(s)
Tiparol
Intervention Description
100 mg twice daily
Primary Outcome Measure Information:
Title
Number of Patients Requiring Rescue Medication
Description
Number of patients requiring any further pain medication
Time Frame
7 day study period
Secondary Outcome Measure Information:
Title
Summary of Pain Scores, Day 1-7 of Visual Analogue Scale Grading of Pain
Description
VAS score 1-10 1=no pain 10 = worst possible pain, summary variable day 1-7; 7 - 70
Time Frame
The first 7 days after surgery, during study pain medication
Title
Compliance to Base Medication
Description
Number of patients that did not discontinue study medication before day 7
Time Frame
7-day study period, during study medication
Title
Gastro-intestinal Symptoms
Description
Number of patients reporting any gastro-intestinal side effects; nausea and or vomiting, gastritis etc. assessed by patient and documented in written questionnaire
Time Frame
during the 7- day pain medication period
Title
Dizziness/Sleepiness
Description
Number of patients that experienced dizziness/sleepiness/fatigue, assessed by patient and documented in written questionnaire
Time Frame
During the 7-day pain medication period
Title
Wound Healing
Description
healing process assessed by a blinded physician during the final outpatient clinic visit assessment graded; Good/neutral/bad
Time Frame
16 week follow-up
Title
Satisfaction With Pain Medication
Description
satisfied or unsatisfied with study medication, assessed by patient in questionnaire
Time Frame
during the first 20 days after surgery, 1st outpatient clinic visit
Title
Patient Assessed Overall Satisfaction With Surgery/Outcome
Description
overall satisfaction with outcome, patients assessed satisfaction with the surgical procedure; satisfied, neutral or unsatisfied, written questionnaire.
Time Frame
16 weeks
Title
Patient Assessed Quality of Life
Description
Quality of Life evaluated by grading on a Visual Analogue Scale in the written questionnaireisual analogue scale grading 0-100; 0 death and 100 perfect quality of life
Time Frame
At 16-week post surgery follow-up
10. Eligibility
Sex
Female
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Health ASA 1-2 patients 18-65 years of age
Exclusion Criteria:
ASA/NSAID allergy
Renal disease
Lithium therapy
Complicated cardiovascular disease
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Jan Jakobsson, MD, PhD,
Organizational Affiliation
Foot & Ancle Surgical Center
Official's Role
Principal Investigator
Facility Information:
Facility Name
Foot & Ancle Surgical Center
City
Stockholm
ZIP/Postal Code
11542
Country
Sweden
12. IPD Sharing Statement
Learn more about this trial
The Effect of Anti-inflammatory Analgesics on Pain Following Hallux Valgus Surgery
We'll reach out to this number within 24 hrs